Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2010

View Archived Issues

Further data from IMPACT trials of C1-INH in hereditary angioedema reported

Some clinical benefit of tremelimumab in phase II metastatic gastric/esophageal adenocarcinoma trial

Ixabepilone therapy linked to tumor regression in phase II metastatic renal cell carcinoma trial

Merck & Co. reports new potent and selective GPR109A agonist

GlaxoSmithKline claims novel antibacterial agents

NicOx describes novel nitric oxide-releasing steroids

Merck & Co. and NicOx claim new angiotensin II receptor antagonists

Myriad launched Prolaris to predict prostate cancer recurrence

Bristol-Myers highlights pipeline and biopharmaceutical strategy

SpePharm acquires rights to Savene and partners with Paladin

Kinex begins phase II trial of KX2-391 in bone-metastatic CRPC

Vaxart raises funds for development avian influenza vaccine

U.K. JCVI recommends Intercell's Japanese encephalitis vaccine Ixiaro

BioVex initiates phase I trial of genital herpes vaccine ImmunoVEX-HSV2

Biomoda and Amigenics announce collaboration

Stemgent invests in new biotechnology company Ubiquigent

DSMB supports continuation phase II Doxil trial in platinum-resistant ovarian cancer

Vertex identifies novel PKC-theta inhibitors

Foamix and Therapeutics collaborate to develop inflammatory skin disease therapies

Cell Therapeutics' phase III Opaxio trial in ovarian cancer to continue

Mount Sinai School of Medicine and Medisyn discover new potential Alzheimer's disease therapeutics

Rexahn submits protocol of phase IIb Zoraxel trial in erectile dysfunction to FDA

NeoStem and University of Michigan enter into sponsored research agreement

Merck & Co. presents update on late-stage pipeline following merger with Schering-Plough

Preliminary clinical data support the use of vaginal diazepam

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...